Kornimate/medical-research-clean huggingface dataset:
evaluation of glucofacts® deluxe diabetes management system

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to evaluate a diabetes management program in the hands of potential users, both health care professionals and lay persons.

diabetes data management programs upload glucose meter results to computers to provide information at home to lay people with diabetes and their healthcare professionals to manage their diabetes. the study evaluated the subjects' success using the software program with a blood glucose meter to perform specific tasks, such as uploading the meter results, changing program and meter settings, and displaying reports. the study also evaluated the system's ease of use and the acceptability of product labeling.

Eligibility criteria:
inclusion criteria: lay users must: * be at least 18 years of age (at least 80% must be 55 years or less) * have diabetes or be the parent or legal guardian of a child with diabetes who routinely test their blood sugar at home * be testing blood sugar at home at least twice daily for at least one month or be the parent or legal guardian of a child who has been testing blood sugar at home at least twice daily for at least one month * be able to speak, read, and understand english * have experience using pc programs or browsing the internet * have utilized diabetes management software at home in the last year (at least 75% of lay users) or be familiar with diabetes management software hcps must: * have experience using diabetes data management software in the medical office or assist in patients' diabetes disease management using software exclusion criteria: * person working for a competitive medical device company * person having a cognitive disorder or condition which, in the opinion of the investigator, would put the person at risk or compromise the integrity of the study.
epimix versus ct brain pediatric study

Conditions: Brain Diseases

Summary: this study aims to assess the diagnostic feasibility and diagnostic performance of a new fast mr sequence epimix for neuroradiological evaluation in comparison to computed tomography of brain in pediatric population.

the study aims to assess the feasibility of fast mr sequence for neuroradiological evaluation in comparison to computed tomography of brain in pediatric population. imaging quality is analysed with regards to artefacts and lesion conspicuity as well as its diagnostic potential in rendering a probable diagnosis. the primary study aim is to define feasibility and the auc for diagnostic performance of minute mri compared to computed tomography. included patients are children age 4-18 with suspicion of cerebral pathology with referral to elective computed tomography of the brain. study participants are in addition to computed tomography investigated during same day at 3t mr.

Eligibility criteria:
inclusion criteria: * age 4-18 years. * patient with suspicion of cerebral pathology. * referral to elective brain ct study. exclusion criteria: * ct planned with sedation * known previous cerebral pathology (follow up study) * emergency ct * aborted mr exam

Keywords: mri (magnetic resonance imaging) neuroradiology epimix (echo planar imaging mix) multicontrast epi (echo planar imaging) clinical validation
differential diagnostics of etiology of acute infections

Conditions: Intestinal Infectious Diseases; Neuroinfections

Summary: method for diagnostics of the origin of infections (bacterial vs viral) based on the identification of activation markers of blood neutrophils and monocytes will be developed.

during the study, method for diagnostics of the origin of infections (bacterial vs viral) based on the identification of activation markers of blood neutrophils and monocytes will be developed.this method will allow to make a diagnosis within an hour after blood sampling. the expression of the following markers of activation will be studied using flow cytometry: cd11b, cd11c, cd13, cd16, cd32, cd35, cd38, cd62l, cd64, cd66b, cd88, cd284, hla-abc and hla-dr.

Eligibility criteria:
inclusion criteria: * neuroinfections or acute intestinal infections; * the possibility of blood sampling within a period of up to 24 hours from the moment of admission to hospital; * less than 72 hours passed after the onset of the disease and until blood was collected; exclusion criteria: * refuse of patient to participate in the trial; * more than 24 hours passed after the patient entered the hospital; * the disease began more than 72 hours ago; * concomitant severe acute and chronic diseases; * malignant neoplasms, treatment at a time of less than 1 year, autoimmune diseases in the phase of exacerbation; * pregnancy/lactation; * hiv, hepatites b/c; * active tuberculosis; * alcohol use disorder/drug addiction.

Keywords: acute infections, flow cytometry, cell activation
examining the effects of intra-detrusor botox at time of holep in men with overactive bladder symptoms

Conditions: Urinary Incontinence; Overactive Bladder Syndrome; Overactive Bladder; Urologic Diseases

Summary: the objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor onabotulinumtoxina injections at the time of holium laser enucleation of the prostate (holep) in men with overactive bladder symptoms with and without urge incontinence.

patients with significant preoperative urgency and/or urge urinary incontinence (uui) along with lower urinary tract symptoms (luts) due to benign prostatic hyperplasia (bph) may require post-holep anticholinergic, b-3 agonist, or intravesical onabotulinumtoxina administration. this injection is a guideline recommended for treatment in patients with severe irritative luts (urgency, uui) and overactive bladder.

Eligibility criteria:
inclusion criteria: * males 18 -89 undergoing holep * component of oab symptoms including frequency, nocturia, urgency, and/or urge related incontinence * willing to sign the informed consent form * able to read, understand, and complete patient questionnaires. exclusion criteria: * allergy or hypersensitivity to onabotulinumtoxina injections * patients having a concurrent ureteroscopy +/- laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at the time of their holep * anticipated need for perineal urethrostomy at the time of holep * prior pelvic radiation or patients with a history of bladder cancer with or without bcg therapy * patients who lack decisional capacity * active urinary tract infection
the effects of whole body vibration in people with chronic stroke

Conditions: Stroke

Summary: whole body vibration (wbv) has been found to be useful in promoting bone health and muscle performance in older adults. to date, no study has examined the effects of different wbv frequencies on the properties of the muscle-bone unit in stroke patients. the overall aim of the proposed study is to compare the efficacy of different vibration frequencies on properties of the muscle function and bone turnover among people with chronic stroke. it is hypothesized that the higher-vibration frequency protocol will lead to significantly better outcomes related to the bone turnover and muscle function.

whole body vibration (wbv) has been found to be useful in promoting bone health and muscle performance in older adults. to date, no study has examined the effects of different wbv frequencies on the properties of the muscle-bone unit in stroke patients. the overall aim of the proposed study is to compare the efficacy of different vibration frequencies on properties of the muscle function and bone turnover among people with chronic stroke. it is hypothesized that the higher-vibration frequency protocol will lead to significantly better outcomes related to the bone turnover and muscle function in people with chronic stroke.

Eligibility criteria:
inclusion criteria: 1. a diagnosis of stroke 2. stroke onset \>6 months 3. \>18 years of age 4. able to walk for short distance independently with or without walking aid 5. able to understand simple verbal commands exclusion criteria: 1. neurological conditions other than stroke 2. significant musculoskeletal conditions (e.g. amputations) 3. metal implants in the lower extremity 4. previous fracture of the lower extremity 5. are currently taking bone resorption inhibitors or were taking the same before stroke. 6. significant peripheral vascular disease 7. vestibular disorders 8. pregnancy 9. other serious illnesses that preclude the person from participating in the study

Keywords: vibration bone mucle cerebrovascular accident rehabilitation
changes in skeletal muscle in heart failure

Conditions: Heart Failure

Summary: the mechanisms behind heart failure are largely unknown. despite an increasing arsenal of pharmacological therapies, cardiovascular disease is still the most common cause of death in the western world, which demonstrates a pronounced need for more patient-related mechanistic research. cachexia and limited exercise capacity are the symptoms that best match prediction of heart failure, both of which are symptoms involving a dysfunctional skeletal muscle. an increased understanding of the mechanisms and signaling pathways connects the failure heart with skeletal muscle dysfunction is likely to lead both to discoveries of prognostic factors and possible therapeutic options. the study is a prospective, non-blinded, study. the study will consist of the assignment of patients with heart failure, new york heart association (nyha) iii-iv, 60-80 years old. one hundred (100) patients will be enrolled in this study.

the primary objective is to investigate how changes in the skeletal muscle coincide with changes in physical performance, cardiac function, and prognosis in patients with heart failure, and changes over time. therefore, the investigators will investigate patients with severe heart failure at 'baseline' and on a second follow-up occasion after 12-16 months. the secondary and tertiary objective is to investigate how changes in the metabolic signature of blood and satellite cells coincide with changes in physical performance, cardiac function, and prognosis in patients with heart failure, and changes over time. patient recruitment is expected to occur over 36 months. the study will be conducted in sweden at karolinska university hospital, huddinge.

Eligibility criteria:
inclusion criteria: * signed informed consent * 60-80 years old upon inclusion * chronic heart failure ≥ 45 days. * left ventricular ejection fraction ≤ 35%. * nyha iii-iv * receiving medical management with optimal doses of betablockers, acetylcholinesterase (ace)-inhibitors or angiotensin ii receptor blockers (arb), and mineral receptor antagonists (mra) for at least 30 days if tolerated. exclusion criteria: * interagency registry for mechanically assisted circulatory support (intermacs) profile 1 "crash and burn" * on-going mechanical circulatory support. * severe chronic obstructive pulmonary disease (copd) or severe restrictive lung disease. * psychiatric disease, cognitive dysfunction, alcohol or drug abuse, or psychosocial issues that are likely to impair study compliance * condition, other than heart failure, requiring end-of-life care within \<6 months in time or where the risk of death within \<2 years is considered to be imminent. * participation in studies that resulted in departure from normal treatment routine or invasive investigations within \<6 months back in time.

Keywords: heart failure skeletal muscle exercise capacity lung function gene expression
study of everolimus in the treatment of advanced malignancies in patients with peutz-jeghers syndrome

Conditions: Peutz-Jeghers Syndrome; Neoplastic Processes; Neoplasm Metastasis

Summary: in this pilot study the investigators will treat all patients known with peutz-jeghers syndrome (pjs) who are diagnosed with advanced malignancies with everolimus 10mg daily until disease progression. most patients with pjs have an inherited lkb1 mutation leading to aberrant m-tor activity. their risk to develop malignancies or intestinal polyps is probably related to this constitutive mtor signaling. the hypothesis is that mtor inhibition is an effective anticancer treatment in pjs patients with advanced malignancies.


Eligibility criteria:
tow cohorts of pjs patients will be included. cohort 1: advanced malignancy cohort 2: high risk polyps general inclusion criteria: 1. known peutz-jeghers disease (with lkb1 mutation) 2. no concurrent systemic anti cancer treatment 3. no prior treatment with m-tor inhibitor 4. prior malignancies or concurrent second malignancies are allowed 5. prior systemic therapy is permitted with a washout time of at least 4 weeks 6. ecog/ who performance 0-2 7. age \> 18 years 8. adequate renal function (defined as creatinine \< 150 μmol/l) 9. adequate liver function (bilirubin \< 1.5 times upper limit of normal, alat or asat \< 5.0 times upper limit of normal in case of liver metastases and \< 2.5 the upper limit of normal in absence of liver metastases 10. adequate bone marrow function (wbc \> 3.0 x 10 9/l, platelets \> 100 x 10 9/l) 11. absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. 12. no pregnancy or lactating and ifof childbearing potential patients must agree to use a reliable contraceptive method throughout the study 13. no serious concomitant systemic disorder that would compromise the safety of the patient,at the discretion of the investigator 14. signed informed consent according to ich/gcp. 15. no uncontrolled symptomatic hyperglycaemia specific inclusion criteria for cohort 1: 1. cytological or histological confirmed carcinoma 2. metastatic or non-resectable disease 3. patients with clinically and/or radiographically documented measurable lesion according to recist criteria: 1. x-ray, physical exam \> 20 mm 2. spiral ct scan \> 10 mm 3. non-spiral ct scan \> 20 mm specific inclusion criteria for cohort 2: 1. known high risk polyps (definition see page 19) 2. ability to undergo endoscopies specific exclusion criteria: symptomatic pj-polyps, defined as polyps likely to be responsible/causal for the abdominal symptoms the patient presents with.

Keywords: peutz-jeghers syndrome mtor inhibition cancer
to evaluate the safety/tolerability and pharmacokinetics, and pharmacodynamics of dwp14012 injection

Conditions: Erosive Gastroesophageal Reflux Disease

Summary: to evaluate the safety/tolerability and pharmacokinetics, and pharmacodynamics after intravenous dwp14012 injection in healthy participants


Eligibility criteria:
inclusion criteria: 1. healthy adult volunteers aged 19 to 50 at the time of screening tests 2. those who weigh more than 50.0 kg, 90.0 kg or less, and have a bmi of 18.5 or more and 29.9 or less at the time of screening inspection bmi (kg/m2) = weight (kg) / {height (m)}2 3. in the case of female volunteers, those who are not necessarily pregnant or lactating or who are in surgical infertility (bilateral ovarian obstruction, hysterectomy, bilateral ovarian resection, etc.) 4. a person who voluntarily decides to participate after hearing and fully understanding the detailed explanation of this clinical trial and agrees in writing before a screening procedure 5. a person who is suitable for this test when judging the tester by physical examination, clinical laboratory examination, questionnaire, etc exclusion criteria: 1. clinically significant hepatomegaly (severe liver disorder, viral hepatitis, etc.), kidney (severe renal disorder, etc.), nervous system, immune system, respiratory system, digestive system, endocrine system, blood and tumor, cardiovascular system (heart failure, torsades de points, etc.), urinary system, mental system (fever disorder, obsessive compulsive disorder, etc.), sexual dysfunction, etc 2. a person who has a history of gastrointestinal diseases (such as crohn's disease, ulcers, gastritis, gastritis, gastroesophageal reflux disease, etc.) or surgery (except simple appendectomy or hernia) that may affect the safety, pharmacokinetics and pharmacodynamic evaluation of clinical medicines 3. those with genetic problems such as galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption 4. a person who has been tested positive for helicobacter pylori 5. those who have anatomical impairments in insertion and maintenance of the ph meter catheter etc
scapular upward rotation exercises for subjects with deperessed scapular alignment

Conditions: Scapular Dyskinesis

Summary: it was hypothesized that: there is no statistical significant effects of a scapular vupward rotation exercise (sure) on scapular alignment in subjects with scapular downward rotation syndrome (sdrs). there is no statistical significant effects a scapular upward rotation exercise (sure) on mechanosensitivity of the upper limb peripheral nervous system in a depressed scapular alignment subjects. there is no statistical significant effects a scapular upward rotation exercise (sure) on pressure pain threshold in a depressed scapular alignment subjects. there is no statistical significant effects a scapular upward rotation exercise (sure)on strenght duration curve measurement in a depressed scapular alignment subjects.

this study was conducted to investigate the effects of scapular upward rotation exercises on strength duration curve and pressure pain threshold (ppt) in subjects with scapular downward rotation syndrome. thirty subjects with age range of 18 to 30 years with scapular downward rotation were recruited in this study. thirty subjects of both gender with scapular downward rotation were recruited in this study. all recruited subjects were examined to exclude defined pathological conditions. all subjects were assessed by screening examination for downward rotation of scapula. pressure pain threshold was measured using pressure algometer. mechanosensitivity of neural tissue was measured using neurodynamic test. pain was measured using strength-duration (sd) curve. treatment program consisted of 3 sessions/week, for 6 weeks. all measurements were taken pre and post the treatment period.

Eligibility criteria:
inclusion criteria: * university population were screened for subjects with scapular downward rotation, those who met the following criteria was recruited in this study. the inclusion criteria for subject selection in this study was based on the literature (caldwell et al., 2007; ha et al., 2011) which included: 1. the scapula was downwardly rotated by visual appraisal.we examined the root of spine of scapulae (superior angle) and inferior angle of scapulae. if scapulae was downwardly rotated, inferior angle closer to spine than root of spine of scapulae (superior angle). 2. the clavicle appeared to be horizontal or the acromioclavicular joint was lower than the sternoclavicular joint by visual appraisal. 3. the vertebral borders of the scapula was less than 3 inches from the spine by tape measure. exclusion criteria: * subject who has any of the following criteria was excluded from the study: 1. subjects with cervical spinal fractures. 2. neck-rotation rom of \<20º. 3. radiating pain to an upper extremity. 4. scoliosis. 5. leg length discrepancy. 6. a history of unresolved cancer. 7. diabetes miletus. 8. polyneuropathy. 9. myofascial pain syndrome. 10. fibromyalgia.

Keywords: neural tissue mechanosensitivity depressed scapular alignment scapular upward rotation exercises
study on application of suturing parathyroid markers in thyroid cancer surgery

Conditions: Thyroid Cancer; Hypoparathyroidism; Marker; Structural; Complication of Surgical Procedure; Parathyroid Function Low Adverse Event

Summary: to study the protective effect of suture parathyroid marker method on the function of parathyroid gland in thyroid cancer surgery

this is a prospective randomized controlled study.in the experimental group, the suture parathyroid marker method was used to mark the parathyroid gland at the first time when it shows, and this marker was further used to identify and locating the inferior parathyroid marker in subsequent central region dissection. in the control group, the central area was routinely cleaned without suture parathyroid marker .

Eligibility criteria:
inclusion criteria: * patients with thyroid cancer who need central compartment dissection * routine neck incision surgery * patients undergoing primary neck surgery exclusion criteria: * benign thyroid tumor patients * selecting patients with endoscopes, small incisions, or robotic surgery * patients with hyperparathyroidism

Keywords: thyroid cancer hypoparathyroidism parathyroid marker
home-based transcranial direct current stimulation open trial for behavioral and cognitive symptoms in huntington's disease

Conditions: Huntington Disease

Summary: the purpose of this study is to assess feasibility, acceptability, and safety of providing transcranial direct current stimulation( tdcs) to huntingtons disease (hd) patients in the early to middle stages and to assess the efficacy of tdcs for hd-related behavioral, cognitive and other symptoms


Eligibility criteria:
participant: inclusion criteria: * confirmed hd mutation carriers * early (stages 1 and 2) or moderate (stage 3) stages according to shoulson-fahn * exhibit mild to moderate behavioral symptoms, such as clinically diagnosed apathy, irritability, anxiety, depression, aggression and repetition * stable doses of medications for at least one month exclusion criteria: * unstable medical conditions * history of epilepsy * metallic objects in the brain * clinical diagnosis of major cognitive disorder or dementia * have risk of suicidal behavior, defined as any suicidal behavior or suicidal ideation of type 4 caregiver: inclusion criteria: -willingness to participate in the study exclusion criteria: -motor/cognitive symptoms related to alzheimer's disease or huntington's disease that might impair the ability to assist the participant during the research study.

Keywords: transcranial direct current stimulation
combining a smoke ending aid with behavioral treatment - 1

Conditions: Tobacco Use Disorder

Summary: the purpose of this study is to combine a smoke ending aid with behavioral treatment.

the prime objective of this innovative stage i a/b behavioral therapy development research project is to conduct a pilot study under randomized, double-blind, placebo controlled conditions, to provide preliminary estimation of the efficacy of a 6 week accu drop nicotine fading protocol used in conjunction with cigarette tapering to bring about termination of cigarette usage in moderate to heavy smokers (\*15 cpd) who are interested in smoking cessation. both the experimental and control groups in this study will receive six weeks of the manually driven behavioral treatment by experienced and trained therapists. the experimental group (n=30) will also be prescribed active accu drops (ad\&c) while the control condition (n=30) will be prescribed placebo accu drops (pd\&c) very similar in appearance, viscosity, and taste to active accu drops. completion of the study protocol and smoking cessation rates at 1 week, 1 month, and 6 months post-treatment will be the prime measures of efficacy. the findings of this study will provide sufficient preliminary indication for the efficacy of the experimental treatment and its extended investigation in a phase ii study or for its nonefficacy.

Eligibility criteria:
inclusion criteria: * 21 years of age or older, and no greater than 65 years of age * medically stable * smoke at least 15 filtered cigarettes daily * motivated to quit smoking exclusion criteria: * medically unstable * currently psychiatrically unstable (schizophrenia, unstable psychosis, untreated major depression, active substance abuse within the past 6 months) * pregnant

Keywords: nicotine fading accu drop cigarette tapering smoking cessation motivational interviewing